Caribou Biosciences has reported positive long-term follow-up data from the dose escalation portion of the ongoing ANTLER Phase 1 trial. The trial is...

Founded in 2011, Caribou Biosciences is developing novel allogeneic CAR-T cell and CAR-natural killer cell therapies to treat cancer. The UC Berkeley...

In recent years, researchers have turned to gene editing to address the limitations of CAR T therapies. This roundup summarises the clinical-stage...

Caribou Biosciences has reported new 12-month clinical data from its ongoing ANTLER Phase 1 trial of CB-010 for relapsed/refractory B cell non-Hodgkin...

Caribou Biosciences recently shared positive clinical data for its CRISPR-edited CAR-T cell therapy, CB-010, in patients with relapsed/refractory B...

In this piece, we provide selected highlights from the 63rd American Society of Hematology annual meeting, held from December 11-14th 2021.

Some of the best links we picked up around the internet

This week’s update looks at a CRISPR-edited CAR T-cell therapy in clinical development for the treatment of a range of B cell cancers.